+25%

est. 2Y upside i

HealthcareSeries D+

Rank

#1477

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Low

Consider equity opportunity with high risk.

Last updated: July 19, 2026

Bull (25%)+180%

Successful pivotal trial results and a major partnership drive valuation to $1B+ within 2 years; strong moat and clinical progress justify a 3x entry valuation, but capped at 200% upside and net of 20% dilution.

Base (55%)0%

Steady clinical progress with no major catalysts; valuation remains around $400M as company extends runway; dilution offsets modest 20% upside, yielding 0% net return.

Bear (20%)-100%

Clinical trial setback or regulatory failure leads to loss of confidence; with $454M in preferred funding against a $332.6M valuation, common stock recovers nothing.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

136%

$454M total funding vs $332.6M valuation implies preferred stack exceeds current valuation; common has zero equity value until exit > $454M.

Dilution Risk

high

Likely need additional rounds within 2 years given high burn rate.

Secondary Liquidity

none

No secondary market observed.

Technical Operations — 4 roles

Quality — 3 roles

Clinical Development — 1 role

Regulatory Affairs — 1 role

View all 9 open roles at Egenesisbio →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Egenesisbio's data — designed to show you've done your homework.

  • 1

    “How does eGenesis plan to achieve commercial revenue without FDA approval? What is the probability of success for current clinical trials?”

  • 2

    “What are the key regulatory milestones and timelines for the pig kidney program?”

  • 3

    “Given the preference stack, how does the company plan to incentivize and retain employees with equity that is currently under water?”

Community

Valuation Sentiment

Our model estimates +25% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.